Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.
Oncology Ltd, United Kingdom, for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate for the treatment of soft tissue sarcoma.
In February 2013, Nexus Oncology Ltd changed name to Ockham Europe Limited.
The sponsorship was transferred to Merck KGaA, Germany, in March 2015.
(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate
|Disease / condition||
Treatment of soft-tissue sarcoma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.